AMGN
Amgen Inc
Nasdaq Global Select$245.09
Open: $244.66 High: $246.13 Low: $244.08 Close: $245.67
Range: 2022-06-27 - 2022-06-28
Volume:599,691Market: Open
Powered by Finage Stock APIDelayed data
AMGN
Amgen Inc ONE AMGEN CENTER DRIVE https://www.amgen.com
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).- CEO: Robert A. Bradway
- Employees: 24,200
- Sector: Healthcare
- Industry: Biotechnology
AMGN News
Latest news about the AMGN
- Amgen says IRS seeks billions in back taxes, shares fall 6% by Reuters at 4/27/22, 10:32 PMView More →
- Amgen to buy back $6 billion in shares this qtr, provides long-term profit forecast by Reuters at 2/8/22, 7:52 PMView More →
- Amgen plans $6 bln share buyback in Q1, sees earnings doubling by 2030 by Reuters at 2/8/22, 3:36 PMView More →